A biomarker that is strongly associated with triple negative breast cancer, a highly aggressive carcinoma that often has early relapse and metastasis following chemotherapy, has been found by researchers. The newly identified biomarker, a gene called RASAL2, provides a target for developing new therapeutics designed to treat this often deadly disease.